TCI News

DRUG RECALL: Zantac and other Ranitidine-containing medicines

#Providenciales, October 21, 2019 – Turks and Caicos – As a follow up to our previous Press Release that was published on Wednesday, October 2, 2019, the Ministry of Health, Agriculture, Sports and Human Services (MoHASHS) – based on additional information gathered – is alerting all healthcare providers to desist from importing any ranitidine-containing products in light of the recent global recalls. In addition, all providers are asked to remove all ranitidine-containing products from your shelves and stop all supply, distribution and sale of these products to the public.

The MoHASHS is mindful of the current uncertainty that exists and remains alert regarding the ongoing investigations concerning this medicine. We are therefore advising patients, who are currently taking this medicine, to urgently see their physicians, pharmacists or other healthcare providers to discuss how to proceed with their course of treatment. The MoHASHS wishes to advise that there are other suitable alternative treatment options available in the Turks and Caicos Islands.

The recall is due to the presence of low levels of an impurity known as N-nitrosodimethylamine (NDMA) within the recalled medicines. NDMA is classified as a probable cancer-causing agent (carcinogen) based on results from laboratory tests.

Ranitidine, popularly known as Zantac, is both an over-the-counter (OTC) and prescription type drug that reduces the amount of acid created by the stomach. Some of its more common uses include the prevention and treatment of heartburn, indigestion, gastroesophageal reflux disease (GERD) and ulcers of the stomach and intestines.

The MoHASHS’ top priority is to ensure patient safety and we will continue to monitor this situation as investigations continue.

For more information regarding the regulation of controlled drugs, please contact the National Pharmacist, Andre Morgan at 338-3072.

Release: TCIG

Most Popular

To Top